Last reviewed · How we verify
NCT05017610
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
EARLY_PHASE1 trial testing Liothyronine in Recurrent Glioblastoma. Withdrawn.
14 October 2022
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 20 October 2021 |
| Primary completion | 14 October 2022 |
| Estimated completion | 14 October 2022 |
Drugs / interventions tested
- Liothyronine (LIOTHYRONINE) — full drug profile →
- Lomustine (LOMUSTINE) — full drug profile →
- Methimazole — full drug profile →
Conditions studied
- Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
- Recurrent Gliosarcoma — all drugs for Recurrent Gliosarcoma →
Sponsor
Emory University
Who can join
18 and older, any sex, with Recurrent Glioblastoma or Recurrent Gliosarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This early phase I trial studies the safety and feasibility of inducing a hypothyroxinemic state in patients with glioblastoma or gliosarcoma that has come back (recurrent). This trial aims to see if giving a specific thyroid hormone, such as methimazole and liothyronine, is safe and could benefit cancer treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05017610
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liothyronine
Trials testing the same drug.
- NCT04743661 — 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma · Phase 2 · active not recruiting
- NCT04782856 — Energy Metabolism in Thyroidectomized Patients · Phase 2 · completed
- NCT04112316 — Developing Oral LT3 Therapy for Heart Failure - HFrEF · Phase 1, PHASE2 · completed
- NCT03627611 — Identification of Non-responders to Levothyroxine Therapy · Phase 2 · completed
- NCT03098433 — Effects of Liothyronine on Energy Expenditure and Cardiovascular Function · Phase 1, PHASE2 · completed
Other recruiting trials for Recurrent Glioblastoma
Currently open trials in the same condition.
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM · Phase 1 · recruiting
- NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
- NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
- NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05017610 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 2 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05017610.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing